title: Activation of endothelin A receptors contributes to impaired responsiveness of renal mechanosensory nerves in congestive heart failure.
abstract: Increasing renal pelvic pressure results in PGE2-mediated release of substance P, leading to increases in afferent renal nerve activity (ARNA) and natriuresis, that is, a renorenal reflex response. The renorenal reflexes are impaired in congestive heart failure (CHF). Impairment of the renorenal reflexes may contribute to the increased renal sympathetic nerve activity and sodium retention in CHF. Endothelin (ET)-1 contributes to the pathological changes in cardiac and renal function in CHF. Therefore, we examined whether the ETA receptor antagonist BQ123 altered the responsiveness of renal mechanosensory nerves in CHF. The ARNA responses to increasing renal pelvic pressure were suppressed in CHF but not in sham-CHF rats. In CHF, increasing renal pelvic pressure by 7.5 mm Hg before and during renal pelvic perfusion with BQ123 increased ARNA 12% +/- 3% and 21% +/- 3% (p < 0.05 vs. vehicle). In isolated renal pelvises from CHF rats, PGE2 increased substance P release from 5 +/- 0 to 7 +/- 1 pg/min without BQ123 and from 4 +/- 1 to 9 +/- 1 pg/min with BQ123 in the bath (p < 0.01 vs. vehicle). BQ123 had no effect on the ARNA responses or substance P release in sham-CHF. In conclusion, activation of ETA receptors contributes to the impaired responsiveness of renal mechanosensory nerves in CHF rats by a mechanism(s) at the renal sensory nerve endings.
authors.affiliation: Department of Internal Medicine, Department of Veterans Affairs Medical Center, and University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA. ulla-kopp@uiowa.edu
authors.forename: Ulla C
authors.initials: UC
authors.lastname: Kopp
authors.forename: Michael Z
authors.initials: MZ
authors.lastname: Cicha
authors.forename: Susan Y
authors.initials: SY
authors.lastname: Jones
mesh_terms: D000344:Afferent Pathways / Q000503:physiopathology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology; D004195:Disease Models, Animal; D065130:Endothelin A Receptor Antagonists; D006333:Heart Failure / Q000473:pathology / Q000503:physiopathology*; D006874:Hydrostatic Pressure; D007668:Kidney / Q000187:drug effects / Q000294:innervation* / Q000378:metabolism / Q000503:physiopathology*; D007682:Kidney Pelvis / Q000187:drug effects / Q000294:innervation / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008465:Mechanoreceptors / Q000502:physiology*; D009206:Myocardium / Q000473:pathology; D009929:Organ Size; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A / Q000378:metabolism*; D012964:Sodium / Q000652:urine; D013373:Substance P / Q000378:metabolism; D018487:Ventricular Dysfunction, Left / Q000473:pathology / Q000503:physiopathology
chemical_list: D000959:Antihypertensive Agents; D065130:Endothelin A Receptor Antagonists; D010456:Peptides, Cyclic; D044022:Receptor, Endothelin A; D013373:Substance P; D012964:Sodium; D015232:Dinoprostone; C072247:cyclo(Trp-Asp-Pro-Val-Leu)